Recent Updates — CLGN
CollPlant Biotechnologies Ltd. completed its acquisition of LightSolver Ltd., an Israeli developer of photonic computing technology, on September 3, 2026. The transaction diversifies CollPlant's portfolio into high-performance computing alongside its existing regenerative medicine business. Concurrently, the company reported second quarter 2026 financial results showing GAAP revenues of $108,000 and a net loss of $2.7 million. Cash and cash equivalents stood at $2.6 million as of June 30, 2026. CollPlant operates in biotechnology and deep-tech computing.
CollPlant Biotechnologies Ltd filed a Form 6-K to furnish an updated corporate presentation posted on its website on September 17, 2026. The filing does not contain new operational data or financial results but serves as a vehicle for distributing marketing materials regarding the company's strategic acquisition of LightSolver. CollPlant operates in the biotechnology and high-performance computing sectors.
CollPlant Biotechnologies Ltd. appointed Dr. Ruti Ben Shlomi to its Board of Directors on September 4, 2026, effective immediately following the closing of its acquisition of LightSolver Ltd., announced on September 3, 2026. Dr. Ben Shlomi serves as CEO and Co-Founder of LightSolver, a company pioneering high-performance photonic computing using Laser Processing Units (LPUs). This appointment supports CollPlant's strategy to commercialize the acquired deep-tech assets alongside its existing regenerative medicine business. CollPlant Biotechnologies Ltd. operates in the biotechnology and advanced technology sectors, focusing on recombinant human collagen for medical applications and all-optical computing architectures.
CollPlant Biotechnologies Ltd completed its acquisition of LightSolver Ltd on September 3, 2026, pursuant to a Share Purchase Agreement dated August 29, 2026. The transaction utilized an equity-centric structure, involving the issuance of upfront ordinary shares and pre-funded warrants, along with a $5 million cash investment in LightSolver. Additional milestone-based warrants are exercisable upon LightSolver achieving specified technological and commercial objectives. This acquisition marks CollPlant's entry into the high-performance computing and photonics sectors through LightSolver’s Laser Processing Unit technology. CollPlant Biotechnologies Ltd operates in the biotechnology industry, focusing on regenerative medicine and plant-based recombinant human collagen production.
CollPlant Biotechnologies Ltd. entered into a Share Purchase Agreement on August 29, 2026, to acquire LightSolver Ltd., a developer of photonic computing technology. The acquisition is expected to close in late August 2026. Consideration includes 3,734,476 ordinary shares (19.7% of pre-transaction outstanding shares), pre-funded warrants for 6,134,363 shares, and milestone-based warrants for up to 224,078,345 shares. Roli over options for 2,261,966 shares were also issued. Dr. Ruti Ben Shlomi joined CollPlant's board upon closing. This transaction marks CollPlant's entry into the supercomputing and photonics markets while maintaining its regenerative medicine business.